Recent Posts
- Oblato Announces that it has received a Positive Response from the FDA for the use of OKN-007 for patients with high-grade gliomas in an Expanded Access Program
- Oblato Announces Fast Track Designation of OKN-007 for Diffuse Intrinsic Pontine Glioma from the FDA
- Oblato Announces Discussion Outcome with FDA for Development of OKN-007 for Diffuse Intrinsic Pontine Glioma
- Brain cancer survivor marks Thanksgiving milestone
- Brain tumor drug receives rare disease designations from the FDA
Recent Comments